Parse Biosciences’ Post

It's a harsh reality that countless promising healthcare breakthroughs never see the light of day. At Aditxt, we're committed to rewriting that narrative. We're excited to have had the opportunity to showcase our mission on Benzinga this week: discovering, developing, and actualizing breakthrough innovations. Dive into CEO Amro Albanna's interview below.

As R&D teams in #Pharma and #BioTech drive innovation with new modalities and personalized medicines, #TechOps face the challenge of removing roadblocks to #Commercialization – production costs and turnaround times. Geoffrey Zassenhaus shares how we helped the CMC team of a leading biotech collaborate to redesign its production processes to reduce costs by a factor of 25 and time to patient by 50%. https://lnkd.in/eDXbbbhf

Cellares has just closed a major $255 million third-round financing that will be used to complete a highly automated facility in New Jersey for the production of cell therapies. The Series C takes the total raised to date by the California company to almost $355 million and has been led by Koch Disruptive Technologies with Bristol Myers Squibb, DFJ Growth, Willett Advisors LLC, and existing investors Eclipse, Decheng Capital, and 8VC also contributing. Cellares already has a facility in South San Francisco that will make extensive use of robotics and other automation technologies from its modular Cell Shuttle platform when it goes fully online in the first half of 2024. #CDMO #efficiency #scale #celltherapy #cellandgenetherapy #regenerativemedicine #advancedtherapies #automation #celltherapymanufacturing #355m #seriesC #cellshuttleplatform #biotech #biotechnology #biotechnologyindustry #pharma #pharmaceuticals #lifesciences #innovation #scaling #productionfacilities #EU #US #disruptiveinnovation #automatedfacility #verticalintegration #manufacturing #funding #financing #financinggrowth

Cell-based assays play a critical role in assessing potency for traditional biologics and advanced therapeutics. In this webinar, Luke Mercer discusses the development of cell-based potency assay on an automated platform. Register now. https://ow.ly/Swop50Qan4j

I am so proud to be part of a team that holds science innovation at the forefront of their business model! Ask me today how our humanized animal models can accelerate your preclinical research. #cancer #humanizedmice #oncology #AACR #immunology

Big news in #biotechnology and #celltherapy today!

 Exogenus Therapeutics secures strategic funding.  We're thrilled to announce a strategic investment led by 3xP Global, which will boost the development of #Exo-101, a promising biological medicine derived from umbilical cord blood, for regenerative medicine and inflammatory disorders. This investment will be used for scaling-up of production capabilities towards GMP standards, helping to bridge the gap from pre-clinical to clinical stages, positioning us one step closer to reach patients in need. It will also support team growth and expansion of Exogenus Therapeutics pipeline to reach other markets. Find out more about Exogenus Therapeutics at www.exogenus-t.com #ExogenusTherapeutics #3xPGlobal #Biotech #Innovation #HealthCareInvestement

As a CMC leader also supporting marketing at WuXi XDC, I’d like to share this news again which was posted by WuXi XDC’s own new LinkedIn account. WuXi XDC is a leading global CRDMO focused on antibody drug conjugates (ADC) and the broader bioconjugate market. It provides end-to-end contract research, development and manufacturing services for bioconjugates, including ADCs. Its services cover antibody intermediates and other biologics intermediates, chemical payloads and linkers, as well as bioconjugate drug substances and drug products. WuXi XDC and Multitude Therapeutics, a clinical stage biotechnology company renowned for ADC platform technologies, have reached a comprehensive partnership in drug-linker technology, which is co-developed with HySlink Therapeutics (“HySlink”), and CRDMO services spanning from discovery to commercialization. I’d like to take this opportunity to invite you to follow WuXi XDC’s LinkedIn account right NOW. #adc #adcs #antibodydrugconjugates #cdmo #crdmo #collaborations #partnership #partnerships

What are the benefits of outsourcing Next Generation Sequencing (NGS)? Whether you are a researcher in academia, pharma, commercial lab, biotech or clinical diagnostics/trials team, outsourcing NGS services to Sampled could accelerate your research while letting you focus on bringing health innovations to market, faster. Within our Global Integrated Analytical Biorepository we have a range of leading technologies including Illumina Novaseq 6000 and Novaseq X Plus, if you have existing projects you want to get moving quickly, reach out to our team today: https://bit.ly/3uvOB2L Read our blog and learn about the 7 key benefits to outsourcing NGS services in this article: https://bit.ly/3GUvoLI #ngs #nextgenerationsequencing #TeamSampled #genomics #AnalyzeIt

Testing efficacy in multiple #ALS model lines can assure efficacy in clinical trials. We discussed how patient factors are challenging scientists from reaching markets? https://lnkd.in/gFpERB4T